Abstract:According to the prevailing opinion of today about the structure-activity relationship of cardenolides and bufadienolides, the structural requirements for the characteristic cardiotonic action of these compounds can be summarized as follows: cis-fusion of the C and D rings, hydroxyl groups in positions 3β and 14β, and a five- or six-membered unsaturated lactone ring having β-configuration at C14 (1). Most of the experimental data referred to as evidences supporting this opinion have come, however, from the determination of toxic doses in the whole animal, mainly in the cat, rather than from observations of the action of these compounds in isolated hearts. It follows as a natural consequence that the compounds with a rather weak toxicity have been condemned to be inactive, even if they have a strong cardiotonic action, in spite of the fact that such a kind of compounds may actually be more important from the clinical point of view. For example, the compound like dihydrodigitoxin of which the lactone ring is saturated, and the compound like resibufogenin, which have an epoxide ring between C14 and C15 instead of C14-OH, generally believed to be inactive based on the toxicity data in the cat, have recently been found to be fairly active when tested in the isolated heart (2-3). The authors also found that, different from the above-cited opinion, the presence of 3β-OH is not indispensable for the cardiotonic action of the cardenolides ; 3-epi-digitoxigenin was found to have a definite cardiotonic action upon the isolated frog's heart (See Fig. 8). These findings seem to warrant reexamination of the problem, on the basis of the action of these compounds in the isolated heart. In recent years several adrenocortical steroids and aldosterone antagonists have been reported to be cardiotonic (4-6), despite the fact that their stereochemical structures are essentially different from those of the cardiotonic steroids. In view of these, the authors took up the problem of the cis-fusion of the C and D rings out of the several important points in the structure of cardiotonic steroids as discussed above and reexamined its importance for the specific cardiotonic action using the isolated frog's heart and the heart-lung preparation of the dog.

A Short Review on Cardiotonic Steroids and Their Aminoguanidine Analogues

A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential

Endogenous digitalis: pathophysiologic roles and therapeutic applications

A STUDY ON THE STRUCTURE-ACTIVITY RELATIONSHIP OF THE CARDIOTONIC STEROIDS.

Therapeutic potency of A1 adenosine receptor antagonists in the treatment of cardiovascular diseases, current status and perspectives

The Role of Cardiotonic Steroids in the Pathogenesis of Cardiomyopathy in Chronic Kidney Disease

Digoxin: The good and the bad

Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands

Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids

Aminoguanidine Hydrazone Derivatives: The Antioxidant, Antineoplastic Profile, and Interaction with ctDNA Studies

Exploring The Synthesis of Aminal Guanidine-Based Molecules: Synthesis of Cernumidine and Analogues, and Survey of its Anti-inflammatory Activity

"Cardiac glycosides"-quo vaditis?-past, present, and future?

Endogenous Mammalian Cardiotonic Steroids—A New Cardiovascular Risk Factor?—A Mini-Review

Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine

Comparison of the inotropic potencies of some synthetic and naturally occurring cardiac glycosides using isolated left atrium of guinea pig.

Application of Compounds with Anti‐Cardiac Fibrosis Activity: A Review

Honokiol and magnolol: A review of structure-activity relationships of their derivatives

Recent Advances in the Biological Significance of Xanthine and its Derivatives: A Review

The role of mineralocorticoid receptor antagonists in the prevention and treatment of chronic heart failure after acute myocardial infarction

Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets

Galantamine: A Review Update